ArticleJournal of gastroenterology2023
Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study.
Article in Journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition.Journal of gastroenterology · 2026Guideline
- Efficacy and safety of Vonoprazan-based treatment of Helicobacter pylori infection: a systematic review and network meta-analysis.BMC infectious diseases · 2024Pooled it
- Global status and trends of gastric cancer and gastric microbiota research: a bibliometric analysis.Frontiers in microbiology · 2024Pooled it
- Potassium-competitive acid blockers forFrontiers in cellular and infection microbiology · 2026Review
- Advances in the Management of RefractoryGastro hep advances · 2026Review
- Update on the Management of Helicobacter pylori Infection in Children and Adolescents.Current gastroenterology reports · 2025Review
- Helicobacter pylori Screening and Eradication in Junior High School Students in Yokosuka, Japan: Prevalence, Eradication Rates, and Challenges.Journal of gastroenterology and hepatology · 2025Article
- Role of Vonoprazan-Amoxicillin Dual Therapy in Pediatric RefractoryACG case reports journal · 2025Article
- Long-term evaluation of Helicobacter pylori screening in school health checkups: an 11-year study in Japan.Journal of gastroenterology · 2025Article
- Asia-Pacific Survey on the Management of Helicobacter pylori Infection.Journal of gastroenterology and hepatology · 2025Article
- Case Report: The importance of early intervention for gastroesophageal reflex disease caused by hiatal hernia.Frontiers in pediatrics · 2024Article
- Rights and wrongs ofTherapeutic advances in gastroenterology · 2023Article
- Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-lineFrontiers in pharmacology · 2023Article
- Case report: A pediatric case of repeated false-positive urea breath test forFrontiers in medicine · 2023Article
- Commentary: Association betweenFrontiers in endocrinology · 2023Article
- Important Recommendations Regarding the Test-and-Treat Strategy forInquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVonoprazan (VPZ)-based regimen for Helicobacter pylori (H. pylori) is safe and more efficacious than the proton pump inhibitor-based regimen mainly in adults. This study aimed to evaluate the efficacy and safety of a VPZ-based regimen for H. pylori eradication therapy in adolescents.
methodsAn H. pylori screening and treatment longitudinal project for third-year junior high school students in Saga Prefecture began in 2016. Students who tested positive for both urine and stool tests received a VPZ-based regimen. On the checklist, students were asked for diarrhea, fever, abdominal pain, nausea, vomiting, urticaria, dysgeusia, or bloody stool occurrence during the therapy.
resultsThe longitudinal project for H. pylori screening and treatment among third-grade students in Saga Prefecture targeted 41,115 students from 2017 to 2021 and 836 as positive. Of the 645 students, 542 (84.0% in per protocol [PP] analysis and 73.6% in intention-to-treat [ITT] analysis) were successful in primary eradication therapy. The secondary eradication therapy was successful in 79 (96.3% in PP analysis and 76.7% in ITT analysis) of 82 students. In the primary eradication therapy, abdominal pain occurred in 164 (27.9%), diarrhea in 217 (36.9%), nausea or vomiting in 7 (1.2%), and urticaria in 13 (2.2%) students. In the secondary eradication therapy, abdominal pain occurred in 12 (19.4%) and diarrhea in 17 (27.4%) students. The eradication therapy of 5 students was interrupted due to adverse events only by primary eradication therapy.
conclusionsVPZ-based regimen for H. pylori was efficacious and safe for adolescents, as in adults, for both primary and secondary eradication therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.